Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 12, 2016 - Issue 5
Submit an article Journal homepage
517
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

The shadow of inequitable conduct in the US patent application

Bao-Chi ChangRehabilitation Center, Taipei Veterans General Hospital, Taipei, Taiwan
&
Shyh-Jen WangDivision of Experimental Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan;Institute of Hospital and Health Care Administration and Institute, National Yang-Ming University, Taipei, TaiwanCorrespondence[email protected]
Pages 1318-1320 | Received 29 Oct 2015, Accepted 13 Nov 2015, Published online: 22 Mar 2016

References

  • Wang S-J. The obviousness rejection as a barrier to biotech patent prosecution. Nat Biotech 2009; 27:1125-1126; PMID:20010590; http://dx.doi.org/10.1038/nbt1209-1125
  • Wang S-J. The obviousness rejection as a barrier to vaccine patent prosecution. Human Vaccines 2011; 7:475-477.
  • Wang S-J. The written description rejection as a barrier to biotech patent prosecution. Human Vaccines 2011; 7:569-573; PMID:21552000; http://dx.doi.org/10.4161/hv.7.5.14358
  • Durham A. Patent Law Essentials. Westport, CT: Quorum Books, 1999.
  • Kingsdown Med. Consultants, Ltd. v. Hollister Inc., United States Court of Appeals for the Federal Circuit. 863 F.2d 867, 1988.
  • Wang S-J. The patent portfolio for biotech inventions. Nat Biotech 2013; 31:501-503; PMID:23752433; http://dx.doi.org/10.1038/nbt.2598
  • Therasense, Inc. v. Becton, Dickinson & Co, United States Court of Appeals for the Federal Circuit. 649 F.3d 1276, 2011.
  • Mammen C. Controlling the “Plague”: Re-forming the doctrine of inequitable conduct. Berkeley Tech Law J 2009; 24:1329-1398.
  • Burlington Indus. v. Dayco Corp., United States Court of Appeals for the Federal Circuit. 849 F.2d 1418, 1988.
  • Aventis Pharma S.A. v. Amphastar Pharm., Inc., United States Court of Appeals for the Federal Circuit. 525 F.3d 1334, 2008.
  • Therasense, Inc. v. Beckton, Dickinson and Co., the United States Court of Appeals for the Federal Circuit 593 F.3d 1289, 2010.
  • Molins PLC v. Textron, United States Court of Appeals for the Federal Circuit. 48 F.3d 1172, 1995.
  • Star Scientific Inc. v. R.J. Reynolds Tobacco Co., United States Court of Appeals for the Federal Circuit. 537 F.3d 1357, 2008.
  • Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJA, Pavlakis N, Arnold D, Gibbs P, et al., Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Exp Rev Anticancer Ther Dec 2014; 14:1477-1493.
  • Wang S-J. “The ‘real world’ barriers and solutions to Candida vaccine patent prosecutions: An analysis of US Patent and Trademark Office actions on related applications. Hum Vaccines & Immunotherapeutics 2012; 8:1443-1449; PMID:22894949; http://dx.doi.org/10.4161/hv.21184

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.